FindTrial
Sign In

Peripheral blood mononuclear cell implantation for patients with severe ischemic heart disease

Peripheral blood mononuclear cell implantation for patients with severe ischemic heart disease - PROCEED

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001289
Enrollment
30
Registered
2008-08-03
Start date
2008-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe ischemic heart disease

Interventions

CABG+injection of 10^7 autologous peripheral blood mononuclear cells CABG+injection of 10^8 autologous peripheral blood mononuclear cells

Sponsors

Department of Cardiovascular Science and Medicine,Graduate School of Medicine,Chiba University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient with severe ischemic heart disease and remained ischemic area after CABG.

Exclusion criteria

Exclusion criteria: shock emergency operation malignant neoplasm severe retinopathy severe renal dysfunction(including who receiving chronic hemotherapy) femail with pregnancy others

Design outcomes

Primary

MeasureTime frame
Safety throughout this treatment.—

Secondary

MeasureTime frame
Improvement of regional left ventriculer ejection fraction, gloval left ventriculer ejection fraction, perfusion, ischemic mitral regurgitation, symptom.—

Countries

Japan

Contacts

Public ContactTohru Minamino

Graduate School of Medicine,Chiba University Department of Cardiovascular Science and Medicine

t_minamino@yahoo.co.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026